In non-small cell lung cancer (NSCLC), mutations in two oncogenic driver genes, EGFR and ALK, make up ~25–40% of all NSCLC cases (Kwak et al., 2010; Melosky, 2014). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.